Workflow
研判2025!中国胰酶肠溶胶囊行业产业链、市场规模、企业分析及发展趋势分析:下游需求增长,拉动行业规模至70亿元以上[图]
Chan Ye Xin Xi Wang·2025-07-08 01:42

Core Insights - The number of chronic pancreatitis patients has been increasing significantly, drawing attention from the medical community. The causes are complex and cannot be attributed to a single factor, with poor dietary habits playing a crucial role. Long-term high-fat, high-protein diets, excessive alcohol consumption, and frequent consumption of spicy foods are potential triggers for chronic pancreatitis. The condition leads to chronic inflammation and loss of pancreatic function, and enteric-coated pancreatic enzyme capsules can alleviate the adverse effects caused by insufficient pancreatic secretion, thus treating chronic pancreatitis. The rising number of patients directly drives the demand for enteric-coated pancreatic enzyme capsules, with the market size in China projected to reach 7.11 billion yuan in 2024, reflecting a year-on-year increase of 13.94% [1][11]. Industry Overview - Enteric-coated pancreatic enzyme capsules are digestive aids primarily composed of a mixture of various enzymes extracted from pig pancreas, including protease, lipase, and amylase. Their main function is to supplement the body's required enzymes to improve digestive issues caused by enzyme deficiency or insufficient secretion. The capsules promote fat digestion, assist protein breakdown, facilitate carbohydrate metabolism, alleviate digestive discomfort, and aid in the absorption of fat-soluble vitamins. Adverse reactions are rare, with occasional occurrences of diarrhea, constipation, stomach discomfort, nausea, and skin reactions [3][9]. Market Dynamics - The market for enteric-coated pancreatic enzyme capsules includes several brands such as "Demeitong," "Dashutong," "Chongming," and "Jiayi." The primary products are produced by companies located in Chongqing, Sichuan, and Anhui, with a high market concentration. The competitive landscape is characterized by a variety of brands available in pharmacies and hospitals, with four companies holding production licenses [15][16]. Demographic Trends - The population aged 65 and above in China has been steadily increasing, with projections indicating growth from 177.67 million in 2019 to 219.69 million in 2024, representing an increase in the proportion of elderly individuals from 12.6% to 15.6% of the total population. This demographic shift, often linked to declining birth rates and increased life expectancy, correlates with a higher incidence of chronic diseases and gastrointestinal issues, thereby increasing the demand for enteric-coated pancreatic enzyme products [7][20]. Competitive Landscape - The competitive landscape of the enteric-coated pancreatic enzyme capsule industry is becoming more diverse, with numerous companies entering the market. The market is fragmented, with no single company dominating. As the market expands, companies with innovative capabilities, market sensitivity, and brand advantages are expected to stand out [21][22]. Future Trends - The demand for enteric-coated pancreatic enzyme capsules is anticipated to continue growing due to the aging population and rising incidence of digestive system diseases. Additionally, the market is expected to see increased competition and a shift towards personalized and differentiated products, as companies invest in research and development to meet the diverse needs of different patient groups [20][23].